Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Phase 2
Recruiting
- Conditions
- Non-squamous NSCLC
- Interventions
- Biological: PembrolizumabBiological: BevacizumabDietary Supplement: Folic acid 350-1000 μgDietary Supplement: Vitamin B12 1000 μg
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05751187
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial
Not Applicable
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Device: mixed reality guided localization
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT05715996
- Locations
- 🇨🇳
Zuodong Song, Shanghai, Shanghai, China
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
Recruiting
- Conditions
- NSCLCNSCLC Stage IVNSCLC, Recurrent
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05701787
- Locations
- 🇨🇳
Xiaomin Niu, Shanghai, Shanghai, China
Molecular Analysis and Treatment Options of Thymic Malignancies
Recruiting
- Conditions
- Thymic Epithelial TumorThymic CarcinomaThymic Cancer
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05667948
- Locations
- 🇨🇳
Xiaomin Niu, Shanghai, Shanghai, China
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05650216
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell CarcinomasConcurrent ChemoradiotherapyImmunotherapyChemotherapy
- Interventions
- Drug: chemotherapy combined with PD-1 inhibitors
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05621707
Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation
Not Applicable
Not yet recruiting
- Conditions
- Atrial FibrillationCatheter Ablation
- Interventions
- Procedure: Acupuncture plus morphine
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05575544
mCBCT in Combination With ENB for the Diagnosis of PPNs
Recruiting
- Conditions
- Peripheral Pulmonary NodulesLung Cancer
- Interventions
- Device: Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 109
- Registration Number
- NCT05518669
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Feasibility of Thin Cp-EBUS Scope BF-UC290F for the Diagnosis of PPLs
Not Applicable
- Conditions
- Peripheral Pulmonary Nodules
- Interventions
- Device: Linear Ultrasound Bronchoscope BF-UC290F (Olympus)
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05512533
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
China Lung Cancer Screening (CLUS) Study Version 3.0
Not Applicable
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Other: Whole-process management softwareDevice: LDCT detection
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 100000
- Registration Number
- NCT05494021
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath